Skip to main content
Log in

Hypertensive labeling (reply to Dr. Birkenhäger's editorial)

  • Letter To The Editor
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Birkenhäger WH. Hypertensive labeling: Does it have therapeutic implications?Cardiovasc Drugs Ther 1993;7:207–209.

    Google Scholar 

  2. Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension.Lancet 1982;1:185–191.

    Google Scholar 

  3. Kannel WB. Contribution of the Framingham Study to preventive cardiology.J Am Coll Cardiol 1990;15:206–211.

    Google Scholar 

  4. Julius S. Hemodynamic and neurohumoral evidence of multifaceted pathophysiology in human hypertension.J Cardiovasc Pharmacol 1990;15(Suppl 5):S53-S58.

    Google Scholar 

  5. Lund-Johansen P. Hemodynamics in early essential hypertension. Acta Med Scand 1967;181(Suppl 482):42–43.

    Google Scholar 

  6. Rostrup M, Kjeldsen SE, Eide IK. Awareness of hypertension increases blood pressure and sympathetic responses to cold pressor test.Am J Hypertens 1990;3:912–917.

    Google Scholar 

  7. Lund-Johansen P. Twenty-year follow-up of hemodynamics in essential hypertension during rest and exercise.Hypertension 1991;18(Suppl 3):S54-S61.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lund-Johansen, P. Hypertensive labeling (reply to Dr. Birkenhäger's editorial). Cardiovasc Drug Ther 7, 727–728 (1993). https://doi.org/10.1007/BF00877827

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00877827

Key Words

Navigation